Conversations with policy makers
‘The traditional business model for drug development does not work well for antibiotics,’ says our CEO Van Leeuwen in a recent webinar organized by the Dutch Association of pharmaceutical companies VIG.
‘That is why you now see that the development of new antibiotics is lagging far behind the growing need.’ With antibiotics, finances work fundamentally differently than with drugs for cancer, for example, he explains.
For Madam Therapeutics, this means that we need to deliver more than just science. For us, bringing a much needed new cure for infectious disease to market we need to bot develop state of the art medicines, but also create awareness amongst policticans about the so-called broken business model.
For this reason, Remko van Leeuwen joined as board member of the BEAM Alliance (Biotech companies in Europe combating AntiMicrobial Resistance). This is a strong Network of approx. 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance.
BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe.
